Market capitalization | $85.38m |
Enterprise Value | $6.08m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 55.27 |
P/S ratio (TTM) P/S ratio | 776.18 |
P/B ratio (TTM) P/B ratio | 0.97 |
Revenue (TTM) Revenue | $110.00k |
EBIT (operating result TTM) EBIT | $-57.27m |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
5 Analysts have issued a InflaRx N.V. forecast:
5 Analysts have issued a InflaRx N.V. forecast:
Dec '23 |
+/-
%
|
||
Net Profit | -46 -46 |
49%
49%
|
|
Depreciation and Amortization | 0.61 0.61 |
3%
3%
|
|
Stock Compensation | 3.69 3.69 |
42%
42%
|
|
Operating Cash Flow | -41 -41 |
15%
15%
|
|
Investments | 0.09 0.09 |
47%
47%
|
|
Dividend Paid | - - |
-
|
|
Free Cash Flow | -41 -41 |
15%
15%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a. Its products includes IFX-1 and IFX-2. The company was founded by Niels Christoph Riedemann, Renfeng Guo and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.
Head office | Netherlands |
CEO | Niels Riedemann |
Employees | 66 |
Founded | 2007 |
Website | www.inflarx.de |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.